Your browser doesn't support javascript.
loading
Rationale and design of REGINA, a phase II trial of neoadjuvant regorafenib, nivolumab, and short-course radiotherapy in stage II and III rectal cancer.
Bregni, Giacomo; Vandeputte, Caroline; Pretta, Andrea; Senti, Chiara; Trevisi, Elena; Acedo Reina, Elena; Kehagias, Pashalina; Liberale, Gabriel; Moretti, Luigi; Bali, Maria Antonietta; Demetter, Pieter; Flamen, Patrick; Carrasco, Javier; D'Hondt, Lionel; Geboes, Karen; Gokburun, Yeter; Peeters, Marc; Van den Eynde, Marc; Van Laethem, Jean-Luc; Vergauwe, Philippe; Chapot, Camille Anastasia; Buyse, Marc; Deleporte, Amelie; Hendlisz, Alain; Sclafani, Francesco.
Afiliação
  • Bregni G; Department of Medical Oncology, Institut Jules Bordet - Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Vandeputte C; GUTS Lab, Department of Medical Oncology, Institut Jules Bordet - Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Pretta A; Department of Medical Oncology, Institut Jules Bordet - Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Senti C; Department of Medical Oncology, Institut Jules Bordet - Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Trevisi E; Department of Medical Oncology, Institut Jules Bordet - Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Acedo Reina E; GUTS Lab, Department of Medical Oncology, Institut Jules Bordet - Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Kehagias P; GUTS Lab, Department of Medical Oncology, Institut Jules Bordet - Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Liberale G; Department of Surgery, Institut Jules Bordet - Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Moretti L; Department of Radiotherapy, Institut Jules Bordet - Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Bali MA; Department of Radiology, Institut Jules Bordet - Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Demetter P; Department of Pathology, Institut Jules Bordet - Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Flamen P; Department of Nuclear Medicine, Institut Jules Bordet - Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Carrasco J; Grand Hôpital de Charleroi, Charleroi, Belgium.
  • D'Hondt L; CHU UCL Namur, Site Godinne, Yvoir, Belgium.
  • Geboes K; Department of Gastroenterology, Universitair Ziekenhuis Gent, Ghent, Belgium.
  • Gokburun Y; CHR Namur, Namur, Belgium.
  • Peeters M; Department of Oncology, Universitair Ziekenhuis Antwerpen, Antwerp, Belgium.
  • Van den Eynde M; Institut Roi Albert II, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium.
  • Van Laethem JL; Hôpital Erasme - Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Vergauwe P; AZ Groeninge, Groeninge, Belgium.
  • Chapot CA; Clinical Trial Support Unit (CTSU), Department of Medical Oncology, Institut Jules Bordet - Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Buyse M; International Drug Development Institute, Louvain-la-Neuve, Belgium.
  • Deleporte A; Department of Medical Oncology, Institut Jules Bordet - Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Hendlisz A; Department of Medical Oncology, Institut Jules Bordet - Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Sclafani F; Department of Medical Oncology, Institut Jules Bordet - Université Libre de Bruxelles (ULB), Brussels, Belgium.
Acta Oncol ; 60(4): 549-553, 2021 Apr.
Article em En | MEDLINE | ID: mdl-33435735
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Retais / Terapia Neoadjuvante Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Retais / Terapia Neoadjuvante Idioma: En Ano de publicação: 2021 Tipo de documento: Article